A Combination Vaccine Consisting of Three Live Attenuated Enterotoxigenic Escherichia coli Strains Expressing a Range of Colonization Factors and LTB is Well Tolerated and Immunogenic in a Placebo-Controlled Double-Blind Phase 1 Trial in Healthy Adults
This article, published in Clinical and Vaccine Immunology, describes the results of a Phase 1 trial of a trivalent, live attenuated enterotoxigenic Escherichia coli vaccine candidate, ACE527. The study indicated that ACE527 had a strong safety profile and promising initial immunological data, warranting further clinical testing.
Author(s): Harro C, Sack D, Bourgeois AL, et al.
Published: 2011
Visit web page (English)
(Located at cvi.asm.org)
Citation: Harro C, Sack D, Bourgeois AL, et al. A Combination Vaccine Consisting of Three Live Attenuated Enterotoxigenic Escherichia coli Strains Expressing a Range of Colonization Factors and LTB is Well Tolerated and Immunogenic in a Placebo-Controlled Double-Blind Phase 1 Trial in Healthy Adults. Clinical and Vaccine Immunology. 2011;18(12):2118-2127.
Resource types: Peer-reviewed journal
Diseases: Shigellosis and enterotoxigenic Escherichia coli (ETEC)
Topics: Disease/vaccine specific information
Regions: Global
